{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:54:26Z","timestamp":1753880066764,"version":"3.41.2"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017624","name":"Achaogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017624","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Plazomicin is a new FDA-approved aminoglycoside antibiotic for complicated urinary tract infections (cUTI). In the product labeling, trough-based therapeutic drug management (TDM) is recommended for cUTI patients with renal impairment to prevent elevated trough concentrations associated with serum creatinine increases of \u22650.5\u2009mg\/dl above baseline.<\/jats:p>","DOI":"10.1128\/aac.00148-19","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T13:18:54Z","timestamp":1563974334000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection"],"prefix":"10.1128","volume":"63","author":[{"given":"Tomefa E.","family":"Asempa","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie D.","family":"Seroogy","sequence":"additional","affiliation":[{"name":"Achaogen, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison S.","family":"Komirenko","sequence":"additional","affiliation":[{"name":"Achaogen, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"doi-asserted-by":"publisher","key":"e_1_3_2_2_2","DOI":"10.3810\/pgm.12.2000.suppl11.57"},{"doi-asserted-by":"publisher","key":"e_1_3_2_3_2","DOI":"10.1093\/cid\/ciq257"},{"doi-asserted-by":"publisher","key":"e_1_3_2_4_2","DOI":"10.1093\/cid\/cir202"},{"doi-asserted-by":"publisher","key":"e_1_3_2_5_2","DOI":"10.1016\/j.tim.2014.04.007"},{"doi-asserted-by":"publisher","key":"e_1_3_2_6_2","DOI":"10.1086\/313692"},{"doi-asserted-by":"publisher","key":"e_1_3_2_7_2","DOI":"10.2146\/ajhp140564"},{"doi-asserted-by":"publisher","key":"e_1_3_2_8_2","DOI":"10.1128\/aac.39.3.650"},{"doi-asserted-by":"publisher","key":"e_1_3_2_9_2","DOI":"10.1093\/jac\/39.6.677"},{"key":"e_1_3_2_10_2","volume-title":"Zemdri (plazomicin) injection package insert","author":"Achaogen, Inc","year":"2018","unstructured":"Achaogen, Inc. 2018. Zemdri (plazomicin) injection package insert. Achaogen, Inc., South San Francisco, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210303Orig1s000lbl.pdf."},{"doi-asserted-by":"publisher","key":"e_1_3_2_11_2","DOI":"10.1128\/AAC.00572-10"},{"doi-asserted-by":"publisher","key":"e_1_3_2_12_2","DOI":"10.1586\/eri.12.25"},{"doi-asserted-by":"publisher","key":"e_1_3_2_13_2","DOI":"10.1021\/acsinfecdis.8b00001"},{"doi-asserted-by":"publisher","key":"e_1_3_2_14_2","DOI":"10.1128\/AAC.02744-13"},{"doi-asserted-by":"publisher","key":"e_1_3_2_15_2","DOI":"10.1128\/AAC.00313-18"},{"doi-asserted-by":"publisher","key":"e_1_3_2_16_2","DOI":"10.1128\/AAC.00236-18"},{"doi-asserted-by":"publisher","key":"e_1_3_2_17_2","DOI":"10.1128\/AAC.01074-18"},{"doi-asserted-by":"publisher","key":"e_1_3_2_18_2","DOI":"10.1056\/NEJMoa1801467"},{"doi-asserted-by":"publisher","key":"e_1_3_2_19_2","DOI":"10.1517\/17425255.1.3.351"},{"doi-asserted-by":"publisher","key":"e_1_3_2_20_2","DOI":"10.1055\/s-2007-996406"},{"doi-asserted-by":"publisher","key":"e_1_3_2_21_2","DOI":"10.1016\/j.ccc.2010.11.006"},{"doi-asserted-by":"publisher","key":"e_1_3_2_22_2","DOI":"10.1128\/AAC.01314-10"},{"doi-asserted-by":"publisher","key":"e_1_3_2_23_2","DOI":"10.1128\/AAC.02329-18"},{"doi-asserted-by":"publisher","key":"e_1_3_2_24_2","DOI":"10.1016\/S0272-6386(86)80103-2"},{"doi-asserted-by":"publisher","key":"e_1_3_2_25_2","DOI":"10.1046\/j.1525-1497.1998.00224.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1469-0691.2000.00105.x","article-title":"Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally?","volume":"6","author":"Beaucaire G","year":"2000","unstructured":"Beaucaire G. 2000. Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect 6:357\u2013362.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_2_27_2","volume-title":"American Society for Microbiology Microbe (ASM),","author":"Bhavnani SM","year":"2018","unstructured":"Bhavnani SM, Hammel JP, Trang M, Kim A, Krause KM, Castanheira M, Rubino CM, Ambrose PG, Drusano GL. 2018. Pharmacokinetic-pharmacodynamic target attainment analyses to support plazomicin dose selection and recommendations for interpretive criteria for in vitro susceptibility testing for Enterobacteriaceae, poster #518. American Society for Microbiology Microbe (ASM), Atlanta, GA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00148-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00148-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:32:24Z","timestamp":1645479144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00148-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1128\/AAC.00148-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00148-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00148-19"}}